Perfuse Therapeutics

Bayer announced it has completed the acquisition of Perfuse Therapeutics, a biopharmaceutical company focused on developing treatments for ischemia-induced ocular diseases.

https://www.businesswire.com/news/home/20260505596100/en/Bayer-to-Acquire-Perfuse-Therapeutics-to-Complement-Ophthalmology-Pipeline?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmark The post Bayer to Acquire Perfuse Therapeutics to Complem

PER-001 intravitreal implant shows potential to be the first disease-modifying treatment for both glaucoma and diabetic retinopathyProgressive vision loss reversed in glaucoma patients as optic nerve blood flow and structure improvedDiabetic retinopathy p

- A single intravitreal administration of PER-001 improved both visual function and anatomic structure compared to control at 24 weeks -- These data support the potential of PER-001 as the first disease-modifying treatment for glaucoma --PER-001 improved

- A single intravitreal administration of PER-001 improved both visual function and anatomic structure compared to control at 24 weeks - - These data support the potential of PER-001 as the first disease-modifying treatment for glaucoma - -PER-001 improve

Perfuse Therapeutics, Inc. ("Perfuse Therapeutics"), a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases, today announced that an oral presentation on PER-001 intravitreal implant for glaucoma has be

- Oral presentation to highlight 6-month data from all cohorts of the completed Phase 1/2a clinical trial - SAN FRANCISCO, Calif., April 21, 2025 - Perfuse Therapeutics, Inc. ("Perfuse Therapeutics"), a biopharmaceutical company pioneering transformationa